Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Exelixis, Inc. stock logo
EXEL
Exelixis
$45.91
+3.6%
$41.71
$21.86
$49.62
$12.08B0.282.49 million shs6.04 million shs
Labcorp Holdings Inc. stock logo
LH
Labcorp
$261.89
+0.7%
$251.44
$198.96
$265.72
$21.76B0.82640,698 shs271,298 shs
Medpace Holdings, Inc. stock logo
MEDP
Medpace
$321.50
-1.4%
$303.28
$250.05
$459.77
$9.37B1.47373,876 shs175,561 shs
PRA Health Sciences, Inc. stock logo
PRAH
PRA Health Sciences
$165.21
$167.50
$93.00
$175.95
$10.70B1.31837,472 shs57 shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Exelixis, Inc. stock logo
EXEL
Exelixis
+3.63%+6.54%+7.59%+32.80%+109.06%
Labcorp Holdings Inc. stock logo
LH
Labcorp
+0.72%+1.86%+4.51%+17.71%+28.31%
Medpace Holdings, Inc. stock logo
MEDP
Medpace
-1.39%+4.79%+5.04%+11.98%-20.24%
PRA Health Sciences, Inc. stock logo
PRAH
PRA Health Sciences
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Exelixis, Inc. stock logo
EXEL
Exelixis
4.7526 of 5 stars
2.31.00.04.33.52.54.4
Labcorp Holdings Inc. stock logo
LH
Labcorp
4.3912 of 5 stars
2.42.02.54.22.92.51.3
Medpace Holdings, Inc. stock logo
MEDP
Medpace
4.4617 of 5 stars
2.12.00.04.62.14.22.5
PRA Health Sciences, Inc. stock logo
PRAH
PRA Health Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Exelixis, Inc. stock logo
EXEL
Exelixis
2.52
Moderate Buy$43.56-5.13% Downside
Labcorp Holdings Inc. stock logo
LH
Labcorp
2.79
Moderate Buy$276.085.42% Upside
Medpace Holdings, Inc. stock logo
MEDP
Medpace
2.21
Hold$344.827.25% Upside
PRA Health Sciences, Inc. stock logo
PRAH
PRA Health Sciences
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest MEDP, PRAH, EXEL, and LH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/30/2025
Exelixis, Inc. stock logo
EXEL
Exelixis
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$47.00 ➝ $53.00
6/25/2025
Labcorp Holdings Inc. stock logo
LH
Labcorp
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingCautious ➝ Cautious
6/25/2025
Labcorp Holdings Inc. stock logo
LH
Labcorp
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetEqual Weight ➝ Equal Weight$250.00 ➝ $275.00
6/24/2025
Exelixis, Inc. stock logo
EXEL
Exelixis
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$50.00
6/24/2025
Exelixis, Inc. stock logo
EXEL
Exelixis
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeEqual Weight ➝ Overweight$29.00 ➝ $60.00
6/24/2025
Medpace Holdings, Inc. stock logo
MEDP
Medpace
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform ➝ Equal Weight$300.00
6/23/2025
Exelixis, Inc. stock logo
EXEL
Exelixis
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
6/23/2025
Exelixis, Inc. stock logo
EXEL
Exelixis
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$43.00 ➝ $55.00
6/23/2025
Exelixis, Inc. stock logo
EXEL
Exelixis
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$47.00 ➝ $50.00
6/12/2025
Exelixis, Inc. stock logo
EXEL
Exelixis
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$40.00 ➝ $47.00
6/11/2025
Labcorp Holdings Inc. stock logo
LH
Labcorp
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$270.00 ➝ $283.00
(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Exelixis, Inc. stock logo
EXEL
Exelixis
$2.17B5.77$2.00 per share23.00$7.86 per share5.84
Labcorp Holdings Inc. stock logo
LH
Labcorp
$13.01B1.69$22.58 per share11.60$96.27 per share2.72
Medpace Holdings, Inc. stock logo
MEDP
Medpace
$2.11B4.38$13.76 per share23.37$26.56 per share12.10
PRA Health Sciences, Inc. stock logo
PRAH
PRA Health Sciences
$3.18B3.36$6.09 per share27.11$23.06 per share7.16
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Exelixis, Inc. stock logo
EXEL
Exelixis
$521.27M$2.2020.8718.000.8927.99%28.81%21.94%8/5/2025 (Estimated)
Labcorp Holdings Inc. stock logo
LH
Labcorp
$746M$8.6530.2814.931.655.55%15.27%6.97%7/24/2025 (Estimated)
Medpace Holdings, Inc. stock logo
MEDP
Medpace
$404.39M$13.1024.5423.545.8819.31%54.36%20.81%7/21/2025 (Confirmed)
PRA Health Sciences, Inc. stock logo
PRAH
PRA Health Sciences
$197.04M$3.9050.5226.31N/A6.40%20.49%7.07%N/A

Latest MEDP, PRAH, EXEL, and LH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/24/2025Q2 2025
Labcorp Holdings Inc. stock logo
LH
Labcorp
$4.12N/AN/AN/A$3.49 billionN/A
7/21/2025Q2 2025
Medpace Holdings, Inc. stock logo
MEDP
Medpace
$3.01N/AN/AN/A$537.70 millionN/A
4/29/2025Q1 2025
Labcorp Holdings Inc. stock logo
LH
Labcorp
$3.73$3.84+$0.11$2.52$3.41 billion$3.35 billion
4/21/2025Q1 2025
Medpace Holdings, Inc. stock logo
MEDP
Medpace
$3.06$3.67+$0.61$3.67$528.38 million$558.57 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Exelixis, Inc. stock logo
EXEL
Exelixis
N/AN/AN/AN/AN/A
Labcorp Holdings Inc. stock logo
LH
Labcorp
$2.881.10%N/A33.29%N/A
Medpace Holdings, Inc. stock logo
MEDP
Medpace
N/AN/AN/AN/AN/A
PRA Health Sciences, Inc. stock logo
PRAH
PRA Health Sciences
N/AN/AN/AN/AN/A

Latest MEDP, PRAH, EXEL, and LH Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/10/2025
Labcorp Holdings Inc. stock logo
LH
Labcorp
quarterly$0.721.25%5/29/20256/11/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Exelixis, Inc. stock logo
EXEL
Exelixis
N/A
3.50
3.44
Labcorp Holdings Inc. stock logo
LH
Labcorp
0.68
1.84
1.60
Medpace Holdings, Inc. stock logo
MEDP
Medpace
N/A
0.73
0.73
PRA Health Sciences, Inc. stock logo
PRAH
PRA Health Sciences
0.74
1.21
1.21

Institutional Ownership

CompanyInstitutional Ownership
Exelixis, Inc. stock logo
EXEL
Exelixis
85.27%
Labcorp Holdings Inc. stock logo
LH
Labcorp
95.94%
Medpace Holdings, Inc. stock logo
MEDP
Medpace
77.98%
PRA Health Sciences, Inc. stock logo
PRAH
PRA Health Sciences
93.93%

Insider Ownership

CompanyInsider Ownership
Exelixis, Inc. stock logo
EXEL
Exelixis
2.82%
Labcorp Holdings Inc. stock logo
LH
Labcorp
0.84%
Medpace Holdings, Inc. stock logo
MEDP
Medpace
20.30%
PRA Health Sciences, Inc. stock logo
PRAH
PRA Health Sciences
1.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Exelixis, Inc. stock logo
EXEL
Exelixis
1,147272.71 million265.02 millionOptionable
Labcorp Holdings Inc. stock logo
LH
Labcorp
70,00083.70 million83.00 millionOptionable
Medpace Holdings, Inc. stock logo
MEDP
Medpace
5,90028.74 million22.91 millionOptionable
PRA Health Sciences, Inc. stock logo
PRAH
PRA Health Sciences
18,10064.80 millionN/AOptionable

Recent News About These Companies

PRA Health Sciences
College of Health Sciences & Professions
Accelerating Discovery
PRAH Historical Data
Western University of Health Sciences
Master Of Public Health
Health Sciences Transfer Policies
Interprofessional Education
Mercy College of Health Sciences
Independent/Supplementary Prescribing
Public Health Doctoral Program
Health Sciences Programs
UK insurers need to up their game on cyber gaps, says PRA
Health sciences college takes massive Las Colinas office

New MarketBeat Followers Over Time

Media Sentiment Over Time

Exelixis stock logo

Exelixis NASDAQ:EXEL

$45.91 +1.61 (+3.63%)
Closing price 07/3/2025 03:57 PM Eastern
Extended Trading
$45.95 +0.04 (+0.09%)
As of 07/3/2025 04:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Labcorp stock logo

Labcorp NYSE:LH

$261.89 +1.89 (+0.73%)
Closing price 07/3/2025 03:30 PM Eastern
Extended Trading
$261.87 -0.02 (-0.01%)
As of 07/3/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Labcorp Holdings, Inc. engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.

Medpace stock logo

Medpace NASDAQ:MEDP

$321.50 -4.53 (-1.39%)
Closing price 07/3/2025 02:02 PM Eastern
Extended Trading
$321.18 -0.32 (-0.10%)
As of 07/3/2025 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.

PRA Health Sciences stock logo

PRA Health Sciences NASDAQ:PRAH

PRA Health Sciences, Inc., a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. It operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services. It also provides strategic solutions, such as embedded, functional services provider, staff augmentation, and custom-built development solutions, as well as commercialization services; and early development services for Phase I and Phase IIa studies, as well as bioanalytical analysis. The Data Solutions segment offers data, analytics, technology, and consulting solutions to the life sciences market. Its services include market intelligence services, such as targeting and compensation, and pharmaceutical audit suite services; consulting and services comprising brand analytics, managed markets, commercial effectiveness, and scientific studies/clinical hubs; and technology-enabled products and services that allow clients to access and analyze Symphony Health and integrated third-party data. PRA Health Sciences, Inc. conducts clinical trials in the areas of pharmaceutical development, including oncology, immunology, central nervous system, inflammation, respiratory, cardiometabolic, and infectious diseases. The company was formerly known as PRA Global Holdings, Inc. and changed its name to PRA Health Sciences, Inc. in July 2014. PRA Health Sciences, Inc. was founded in 1976 and is headquartered in Raleigh, North Carolina.